Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures

Overview

Colonoscopy is the most useful exam used to evaluate colorectal diseases, like colorectal polyps and cancer. The appropriate bowel preparation is indispensable for colonoscopy procedures. Polyethylene glycol solution (PEG) is the most frequent laxative medication. However, the taste is poor, and patients need to drink a lot of liquids to obtain adequate visualization of the mucosal surface. In fact, no laxative has all the characteristics of an ideal medication. Lactulose is an osmotic laxative which widely used in cirrhosis and constipation patients, and could inhibit bacterial in the colon to increase colon cleanliness and prolong the effect time of PEG. Previous study demonstrate PEG combined with lactulose has a significant improvement in the quality of bowel preparation compared with PEG alone. The present study aim to assess the efficacy of lactulose with or without PEG in bowel preparation to improve mucosal visualization, reduced volume of fluid consumed, and preparation intolerance.

Full Title of Study: “Effect of Lactulose and/ or Polyethylene Glycol Solution for Bowel Preparation in Colonscopy: a Multi-center Prospective Randomized Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: May 31, 2022

Detailed Description

This study will conduct in 5 clinical central. 1000 participants who were scheduled for colonoscopy age between 18 and 80 years were enrolled in the study. Exclusion criteria were patients with uncontrolled acute or recurrent chronic intestinal infections, with active gastrointestinal bleeding or gastrointestinal stricture or intestinal obstruction, with severity coronary heart disease or heart failure or renal failure and liver failure or severe electrolyte metabolism disorder, with pregnant or lactating or metal diseases or refuse to colonoscopy examination. Central stratification and block randomization is achieved via a computer-generated random-sequence table by using R software. The participants will be assigned into one of four groups at a ratio of 1 : 1, and received a single 3 L dose of either PEG or 200ml dose of lactulose, 100ml lactulose combined with 1L PEG, 100ml lactulose combined with 2L PEG. The following parameters were then obtained: time of the first defecation, defecation frequency, the overall drink liquid volume, the taste of the preparation, the tolerance evaluation, the cleansing quality of the bowel preparations and adverse reaction.

Interventions

  • Drug: 100 ml lactulose combined with 1 L PEG
    • the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
  • Drug: 100 ml lactulose combined with 2 L PEG
    • the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
  • Drug: 200 ml lactulose
    • the participants were instructed to consume 200 ml lactulose alone
  • Drug: 3 L Polyethylene glycol solution
    • the participants were instructed to consume 3000 mL of PEG solution

Arms, Groups and Cohorts

  • Active Comparator: 3 L Polyethylene glycol solution group
    • The participants were instructed to consume 3000 mL of PEG solution
  • Experimental: 100 ml lactulose combined with 1 L PEG group
    • the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
  • Experimental: 100 ml lactulose combined with 2 L PEG group
    • the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
  • Experimental: 200 ml lactulose group
    • the participants were instructed to consume 200 ml lactulose

Clinical Trial Outcome Measures

Primary Measures

  • The quality of bowel preparation
    • Time Frame: up to 12 months
    • to assess the quality of bowel preparation by using Boston Bowel Preparation Scale. The minimum score value is 0,and the maximum value is 9. A higher score means a better outcome. Bowel cleansing was scored by the endoscopist performing the colonoscopy in the single-blind method.
  • The preparation intolerance
    • Time Frame: up to 12 months
    • to assess the preparation intolerance including the palatability of the bowel-cleansing agents, the general satisfaction with the bowel preparation, the willingness to perform another colonoscopy by using case report questionnaire. Moreover, the ratio of drink all preparation fluids and the specific amount of bowel preparation fluid are documented.

Secondary Measures

  • The colorectal diseases detection rate
    • Time Frame: up to 12 months
    • the cecal intubation time, colonoscopy perform time, and polyp detection rate or colorectal cancer detection rate are recorded.
  • The adverse events
    • Time Frame: up to 12 months
    • the adverse events including nausea, vomiting, abdominal pain, abdominal distension, and other adverse reactions after administration are evaluated.

Participating in This Clinical Trial

Inclusion Criteria

  • Participants who were scheduled for colonoscopy age between 18 and 80 years Exclusion Criteria:

  • uncontrolled acute or recurrent chronic intestinal infections – active gastrointestinal bleeding, gastrointestinal stricture, intestinal obstruction – severe electrolyte metabolism disorder, severe coronary heart disease, heart failure, renal failure or liver failure – pregnant, lactating, have metal diseases or refuse to colonoscopy examination

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sichuan University
  • Collaborator
    • Affiliated Hospital of Southwest Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Lin Cai, Principal Investigator – Sichuan University
  • Overall Official(s)
    • juan liao, PhD, Study Director, West China Forth Hospital
  • Overall Contact(s)
    • Lin Cai, MS, +862885503722, cloris58@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.